The HB Reavis developer group is likely to sell three lucrative Prague land plots within a few months. The biggest investors are interested in real estate.
International real estate developer HB Reavis has announced the successful completion of its first unsecured CZK 1.25 billion (EUR 46.2 million) bond issue on the Czech capital market. This brings the total funds raised by HB Reavis through the Central European capital markets since November 2013 to almost EUR 150 million.
HB Reavis’ Metronom Business Center has secured another client. The international biopharmaceutical company AbbVie, which is involved in the research and development of new medications, has moved from its former office on Evropská Street to 1,600 sq m of HB Reavis’ scheme, located in Prague 5. After the recent record-breaking lease of 24 900 sq m to SAP, the Metronom building is now more than 90 percent occupied.
HB Reavis Group and Zeus Capital Management are pleased to announce the completion of the sale and purchase of Váci Corner Offices. HB Reavis Group’s first development in Hungary, located in the heart of the Váci út office corridor in Budapest, has been purchased by a group of investors represented by Zeus Capital Management. This is the first major office transaction in the Hungarian real estate market in 2016, as well as a milestone in the successful business development of HB Reavis in Hungary. This acquisition is made by Zeus Capital Management in relation to its commercial properties investment platform dedicated to Central East and South East Europe.
The HB Reavis group named Petr Herman to the function of Director for the Czech Republic. Until now Mr Herman worked in the position of Business Development Director, and in the last six months he was entrusted with the management of the entire Czech branch. He formerly received experience in upper management positions in Stival Holding, Passerinvest Group and K.P.A.R. consulting.
Contact Us
Do You Have Any Questions?
Tereza Matejkova
+420 210 012 566
Validation
Your choice regarding cookies on this site
We use cookies to optimise site functionality and give you the best possible experience.
This site uses cookies to store information on your computer.
Some of these cookies are essential, while others help us to improve your experience by providing insights into how the site is being used.
Accept Recommended Settings
Necessary Cookies
Necessary cookies enable core functionality such as page navigation and access to secure areas. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytics
Analytical cookies help us to improve our website by collecting and reporting information on its usage.
Marketing
We use marketing cookies to help us improve the relevancy of advertising campaigns you receive.
Social Sharing Cookies
We use some social sharing plugins, to allow you to share certain pages of our website on social media.
